ADC Therapeutics (ADCT) Current Leases (2019 - 2023)

ADC Therapeutics (ADCT) has reported Current Leases for 5 consecutive years, with $1.5 million the latest figure, recorded in Q4 2023.

• Quarterly Current Leases rose 33.73% year-over-year to $1.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.5 million (up 33.73% YoY) and the FY2023 annual result came in at $1.5 million, up 33.73% from the prior year.
• Current Leases climbed to $1.5 million in Q4 2023 per ADCT's latest filing, from $1.4 million in the prior quarter.
• Over the last five years, Current Leases for ADCT reached as high as $1.6 million in Q2 2023 and fell as low as $833000.0 in Q1 2021.
• A 5-year average of $1.1 million and a median of $1.0 million in 2021 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2021 — Current Leases decreased 25.76% — and 2023, when it jumped 79.54%.
• Year by year, Current Leases stood at $924000.0 in 2019, then rose by 8.44% to $1.0 million in 2020, then increased by 2.69% to $1.0 million in 2021, then grew by 6.61% to $1.1 million in 2022, then surged by 33.73% to $1.5 million in 2023.
• According to Business Quant data, Current Leases over the past three periods registered $1.5 million, $1.4 million, and $1.6 million for Q4 2023, Q3 2023, and Q2 2023 respectively.